FDA Greenlights BridgeBio's Heart Drug, Sparking Rivalry with Pfizer
TL;DR Summary
The FDA has approved BridgeBio's drug acoramidis for treating a rare genetic heart disease, setting the stage for market competition with companies like Pfizer and Alnylam.
- FDA approves BridgeBio’s heart disease drug, setting up competition with Pfizer, Alnylam Endpoints News
- BridgeBio wins FDA approval for heart disease drug STAT
- Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients Yahoo Finance
- ATTR-CM Approval for BridgeBio Could Trigger Tight Race With Pfizer BioSpace
- New ATTR-CM drug linked to positive long-term data as FDA nears final decision Cardiovascular Business
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
54%
56 → 26 words
Want the full story? Read the original article
Read on Endpoints News